Ongoing drug trials are seeking to demonstrate, in the next several years, if GLP-1 drugs are effective at treating and/or reducing rates of obstructive sleep apnea, heart failure, NASH (nonalcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis), chronic kidney disease, peripheral arterial disease, joint replacement, osteoarthritis, Alzheimers, cancer and all-cause mortality
"NAT2 global landscape: Genetic diversity and acetylation statuses from a systematic review"
Front Immunol 13:967281 Wang K, Lu J, Song C et al (2024) Extracellular vesicles derived from ligament tissue transport Interleukin-17A to mediate ligament-To-Bone crosstalk in ankylosing Spondylitis
Cng ngh siu dn Liposome c cc hng m phm v cc chuyn gia u t hng triu pht minh ra
While the TRIUMPH-4 results are in, additional trials including TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3 are ongoing or planned